Asthma is a heterogeneous respiratory disease characterized by usually reversible
bronchial obstruction, which is clinically expressed by different phenotypes driven by …

Omalizumab, a human immunoglobulin (Ig) G1 antibody against IgE, is a therapeutic agent
for bronchial asthma. The Global Initiative for Asthma guidelines indicate that the use of …

Introduction Dupilumab is a monoclonal antibody targeting IL-4Rα recently licensed for
severe asthma (SA). A Named Patients Program (NPP) was created in Italy before its …

Severe asthma comprises several heterogeneous phenotypes, underpinned by complex
pathomechanisms known as endotypes. The latter are driven by intercellular networks …

Background Individuals with severe asthma represent 5%–10% of the general asthmatic
population. Despite the use of biologic drugs during clinical management, inadequate …

Asthma is one of the most common chronic respiratory diseases, affecting over 300 million
people worldwide [1]. It is defined by intermittent bronchospasms that cause symptoms such …

Introduction: Asthma as a chronic inflammatory disorder has been suggested as a risk factor
for endothelial dysfunction (ED), but studies on the association between asthma and …

The epithelium, once simply considered a protective barrier against harmful agents, has in
recent times gained considerable relevance as an entity that can pro mote and regulate …

Background Adherence barriers to asthma biologics may not be uniform across
administration settings for patients with moderate-to-severe asthma. Objective To examine …

Background Little is known about adherence to asthma biologics. Research Question Is
adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic …